Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@Bella, if he's been there almost 10 years then he's another one that needs to go as well as, not instead of.
Comms, strategy, financing - all trash.
AstraZeneca has agreed to buy US biopharma company Fusion for up to $2.4bn (£1.9bn), in the group’s latest expansion into cancer treatments.
The company said the deal would help it deliver “on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments”.
Fusion Pharmaceuticals is a clinical stage company developing next-generation radioconjugates.
The medicines help deliver radioactive isotopes directly to cancer cells in a targeted way that minimises damage to healthy cells.
To be fair market conditions are awful.
When money is incredibly tight at Avacta the unforgivable snafu by the CEO are recently splashing tens of millions on dx companies when every man and his dog knows tx is what matters at Avacta. Then due to having limited funds getting hammered by the market in this raise.
And even worse then spinning the notion he will sell of the dx companies so the company can carry on as a going corcern. Just a bonkers situation
They've already given their explanation for 50p - "difficult market conditions". Ignores the clear previous demand from PIs that could have been tapped into. The real reason is mates rates and Alan's ego. Why not give away shares at 50p to get an unnamed specialist fund on board if it makes you feel good. You wouldn't care if you've just awarded yourself another batch of 10p options.
Timster, pffft, mine are the finest quality diamond tipped pitch forks. They'll impale a CFO at 50 yards
Derek for CEO!
Experience
Avacta
9 years 10 months
Group Communications Director
Dec 2020 - Present 3 years 4 months
United Kingdom
Leading on corporate communications for Avacta Group, a UK based clinical stage biotech and diagnostics company.
• Creation and execution of Group communications strategy.
• Support senior leadership with considered counsel on reputation related matters and leading issues preparations and response.
• Managing partnerships with a range of advisors and agencies.
• Investor relations and working within the regulatory framework of being a publicly listed company.
• Media relations
Disagree BV...this is the guy they need to get rid of...
https://uk.linkedin.com/in/michaelvinegrad
And the RNS announcing AS and TG standing down and search starting for new CEO and CFO.
Same point I made previously - the overwhelming majority of shares are still with PI's - and most (me included) will be mightily pi55ed off with Smith. I think we've reached the regrettable stage whereby the CEO being ousted would actually see a rise in the SP!
Timster...Nah..not them..more likely the one who joined on 1 March with 28 neg posts...
AS has a lot of explaining to do. Will he be forthcoming and honest though? That's the question.
Even with the recent raise the huge majority of shares are held with retail. If a vote was pushed I doubt the recent share give away would protect them. It's not just the raise it's the awful comms, DX acquisitions, unrealistic and missed timelines etc. Anyway, see what RNSs land over the next month and explanation re 50p raise
Paul Hill just knows Avacta have a big retail following so adds the hashtag and has AS on to boost his reach. Same goes less successfully for Charles Archer
Back off PL75 I've already got the pitchfork stand in the foyer
Imo, we do need a new CEO and CFO, ones with pharma industry experience and track records of success. However, neither will be voted out by shareholders. The 50p placing to IIs has seen to that. IIs would vote to keep them and IIs will be who AS will now be working to please. It doesn't change the fact that AS's and TG's credibility are shot and irredeemable as far as PIs are concerned.
It’s a couple of guys /girls. With multiple accounts. . We all no that !
Fully agreed - it's more about his own clout than anything else, that's another reason he clings on McPumpy's coat-tails. Anything for clicks on their VOX garbage. If Abakta want to put out any video content why bother pretending that it's an interview as they're always scripted. That said, I wouldn't be surprised if Alan doesn't want to speak to him again as last time - egged on by the twatterati - he asked about funding / strategy and it was thoroughly embarrassing for Alan.
By the way, I'm sharpening my collection of pitch forks if anyone attending the AGM would like to borrow one.
So someone with millions to spend would pay wynbore and Oz to up thier fud antic's?
Is that large trade why we had so many deramping on here...let's see who sticks around eh!
I’ve asked myself that question. Very odd he pushes it so hard, always appears to be in the know. Always cc’s Myles in Twitter.
He’s a parasite.
Bargain of a life time !
Many will have sticky fingers! .
Steady rise once the few 10 percents have moved on !
Somebody jumped the gun and put it through before order filled or what?
18-Mar-24 08:45:14 50.40 -1,000,000 Unknown* -504.00k O
18-Mar-24 08:45:14 50.40 1,000,000 Unknown* 504.00k
Sod AS but the independent clinicians would not be recommending their patients continue to go into hospital to take AVA6000 if they did not believe it was helping. The fact that dox can stabilise or get rid of tumours over a period of less than 5 months and we are able to dose over double that (dose dependent) and these patients won't have the awful side effects it's exciting. Depending on what comes out of the wash over the next month AS and the CFO may have to go and I'm sure they'll need some positive to get the share price a lot higher and some solid reasons why the 50p raise to stop some shareholders forcing an EGM
Wynbore flounced yesterday, yet is back already. Can't trust a word he says.
Who’s the market wyndrum? That’s you and me. In one breath you say:
“All we know for sure is that the wrapper works.”
And then contradict yourself with:
“The market, who actually do have the technical ability to lift the bonnet, is not yet convinced.”
You seem confused as to extent of what we do know and what can be known.